Stina Söderlund

Plasma Protein Profiling to Discern Indolent from Advanced Systemic Mastocytosis

Iribarren, Cristina; Levedahl, Kerstin; Atanasoai, Ionut; Mattsson, Mattias et al.

Ingår i Journal of Molecular Diagnostics, s. 792-804, 2024

• DOI för Plasma Protein Profiling to Discern Indolent from Advanced Systemic Mastocytosis
• Ladda ner fulltext (pdf) av Plasma Protein Profiling to Discern Indolent from Advanced Systemic Mastocytosis

Proteomic and transcriptomic screening demonstrates increased mast cell-derived CCL23 in systemic mastocytosis

Söderlund, Stina; Boey, Daryl; van Midden, Wouter; Kjellander, Matilda et al.

Ingår i Journal of Allergy and Clinical Immunology, s. 205-213, 2023

• DOI för Proteomic and transcriptomic screening demonstrates increased mast cell-derived CCL23 in systemic mastocytosis

Characterization of the bone marrow niche in patients with chronic myeloid leukemia identifies CXCL14 as a new therapeutic option

Dolinska, Monika; Cai, Huan; Mansson, Alma; Shen, Jingyi et al.

Ingår i Blood, s. 73-89, 2023

• DOI för Characterization of the bone marrow niche in patients with chronic myeloid leukemia identifies CXCL14 as a new therapeutic option
• Ladda ner fulltext (pdf) av Characterization of the bone marrow niche in patients with chronic myeloid leukemia identifies CXCL14 as a new therapeutic option

IFN-alfa with dasatinib broadens the immune repertoire in patients with chronic-phase chronic myeloid leukemia

Huuhtanen, Jani; Ilander, Mette; Yadav, Bhagwan; Dufva, Olli M. J. et al.

Ingår i Journal of Clinical Investigation, 2022

• DOI för IFN-alfa with dasatinib broadens the immune repertoire in patients with chronic-phase chronic myeloid leukemia
• Ladda ner fulltext (pdf) av IFN-alfa with dasatinib broadens the immune repertoire in patients with chronic-phase chronic myeloid leukemia

Long-term tolerability and efficacy after initial PegIFN-α addition to dasatinib in CML-CP: Five-year follow-up of the NordCML007 study

Flygt, Hjalmar; Söderlund, Stina; Stentoft, Jesper; Richter, Johan et al.

Ingår i European Journal of Haematology, s. 617-623, 2021

• DOI för Long-term tolerability and efficacy after initial PegIFN-α addition to dasatinib in CML-CP: Five-year follow-up of the NordCML007 study
• Ladda ner fulltext (pdf) av Long-term tolerability and efficacy after initial PegIFN-α addition to dasatinib in CML-CP: Five-year follow-up of the NordCML007 study

Plasma Protein Profiling to Discern Indolent from Advanced Systemic Mastocytosis

Iribarren, Cristina; Levedahl, Kerstin; Atanasoai, Ionut; Mattsson, Mattias et al.

Ingår i Journal of Molecular Diagnostics, s. 792-804, 2024

• DOI för Plasma Protein Profiling to Discern Indolent from Advanced Systemic Mastocytosis
• Ladda ner fulltext (pdf) av Plasma Protein Profiling to Discern Indolent from Advanced Systemic Mastocytosis

Proteomic and transcriptomic screening demonstrates increased mast cell-derived CCL23 in systemic mastocytosis

Söderlund, Stina; Boey, Daryl; van Midden, Wouter; Kjellander, Matilda et al.

Ingår i Journal of Allergy and Clinical Immunology, s. 205-213, 2023

• DOI för Proteomic and transcriptomic screening demonstrates increased mast cell-derived CCL23 in systemic mastocytosis

Characterization of the bone marrow niche in patients with chronic myeloid leukemia identifies CXCL14 as a new therapeutic option

Dolinska, Monika; Cai, Huan; Mansson, Alma; Shen, Jingyi et al.

Ingår i Blood, s. 73-89, 2023

• DOI för Characterization of the bone marrow niche in patients with chronic myeloid leukemia identifies CXCL14 as a new therapeutic option
• Ladda ner fulltext (pdf) av Characterization of the bone marrow niche in patients with chronic myeloid leukemia identifies CXCL14 as a new therapeutic option

IFN-alfa with dasatinib broadens the immune repertoire in patients with chronic-phase chronic myeloid leukemia

Huuhtanen, Jani; Ilander, Mette; Yadav, Bhagwan; Dufva, Olli M. J. et al.

Ingår i Journal of Clinical Investigation, 2022

• DOI för IFN-alfa with dasatinib broadens the immune repertoire in patients with chronic-phase chronic myeloid leukemia
• Ladda ner fulltext (pdf) av IFN-alfa with dasatinib broadens the immune repertoire in patients with chronic-phase chronic myeloid leukemia

Long-term tolerability and efficacy after initial PegIFN-α addition to dasatinib in CML-CP: Five-year follow-up of the NordCML007 study

Flygt, Hjalmar; Söderlund, Stina; Stentoft, Jesper; Richter, Johan et al.

Ingår i European Journal of Haematology, s. 617-623, 2021

• DOI för Long-term tolerability and efficacy after initial PegIFN-α addition to dasatinib in CML-CP: Five-year follow-up of the NordCML007 study
• Ladda ner fulltext (pdf) av Long-term tolerability and efficacy after initial PegIFN-α addition to dasatinib in CML-CP: Five-year follow-up of the NordCML007 study

Successful tyrosine kinase inhibitor discontinuation outside clinical trials - data from the population-based Swedish chronic myeloid leukaemia registry

Flygt, Hjalmar; Sandin, Fredrik; Dahlén, Torsten; Dremaine, Arta et al.

Ingår i British Journal of Haematology, s. 915-921, 2021

• DOI för Successful tyrosine kinase inhibitor discontinuation outside clinical trials - data from the population-based Swedish chronic myeloid leukaemia registry
• Ladda ner fulltext (pdf) av Successful tyrosine kinase inhibitor discontinuation outside clinical trials - data from the population-based Swedish chronic myeloid leukaemia registry

Molecular status 36 months after TKI discontinuation in CML is highly predictive for subsequent loss of MMR: final report from AFTER-SKI

Richter, Johan; Lübking, Anna; Söderlund, Stina; Lotfi, Kourosh et al.

Ingår i Leukemia, s. 2416-2418, 2021

• DOI för Molecular status 36 months after TKI discontinuation in CML is highly predictive for subsequent loss of MMR: final report from AFTER-SKI
• Ladda ner fulltext (pdf) av Molecular status 36 months after TKI discontinuation in CML is highly predictive for subsequent loss of MMR: final report from AFTER-SKI

Plasma proteomics of biomarkers for inflammation or cancer cannot predict relapse in chronic myeloid leukaemia patients stopping tyrosine kinase inhibitor therapy

Söderlund, Stina; Persson, Inger; Ilanderd, Mette; Guilhot, Joelle et al.

Ingår i Leukemia Research, 2020

• DOI för Plasma proteomics of biomarkers for inflammation or cancer cannot predict relapse in chronic myeloid leukaemia patients stopping tyrosine kinase inhibitor therapy

Single-cell analysis reveals the KIT D816V mutation in haematopoietic stem and progenitor cells in systemic mastocytosis

Grootens, Jennine; Ungerstedt, Johanna S.; Ekoff, Maria; Rönnberg, Elin et al.

Ingår i EBioMedicine, s. 150-158, 2019

• DOI för Single-cell analysis reveals the KIT D816V mutation in haematopoietic stem and progenitor cells in systemic mastocytosis
• Ladda ner fulltext (pdf) av Single-cell analysis reveals the KIT D816V mutation in haematopoietic stem and progenitor cells in systemic mastocytosis

Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-line

Kreutzman, Anna; Yadav, Bhagwan; Brummendorf, Tim H.; Gjertsen, Bjorn Tore et al.

Ingår i Oncoimmunology, 2019

• DOI för Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-line
• Ladda ner fulltext (pdf) av Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-line

Advanced phase chronic myeloid leukaemia (CML) in the tyrosine kinase inhibitor era: a report from the Swedish CML register

Söderlund, Stina; Dahlén, Torsten; Sandin, Fredrik; Olsson-Strömberg, Ulla et al.

Ingår i European Journal of Haematology, s. 57-66, 2017

• DOI för Advanced phase chronic myeloid leukaemia (CML) in the tyrosine kinase inhibitor era: a report from the Swedish CML register

Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia.

Ilander, M; Olsson-Strömberg, Ulla; Schlums, H; Guilhot, J et al.

Ingår i Leukemia, s. 1108-1116, 2017

• DOI för Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia.
• Ladda ner fulltext (pdf) av Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia.

Plasma proteomics in CML patients before and after initiation of tyrosine kinase inhibitor therapy reveals induced Th1 immunity and loss of angiogenic stimuli

Söderlund, Stina; Christiansson, Lisa; Persson, Inger; Hjorth-Hansen, Henrik et al.

Ingår i Leukemia Research, s. 95-103, 2016

• DOI för Plasma proteomics in CML patients before and after initiation of tyrosine kinase inhibitor therapy reveals induced Th1 immunity and loss of angiogenic stimuli

Plasma Proteomics In Chronic Myeloid Leukemia Patients Before And After Initiation Of Tyrosine Kinase Inhibitor Therapy Reveals Induced Th1 Immunity And Loss Of Angiogenic Stimuli

Söderlund, Stina; Christiansson, Lisa; Persson, Inger; Hjorth-Hansen, H. et al.

Ingår i Haematologica, s. 730-730, 2016

In vivo CYP3A activity and pharmacokinetics of imatinib in relation to therapeutic outcome in chronic myeloid leukemia patients

Skoglund, Karin; Richter, Johan; Olsson-Strömberg, Ulla; Bergquist, Jonas et al.

Ingår i Therapeutic Drug Monitoring, s. 230-238, 2016

• DOI för In vivo CYP3A activity and pharmacokinetics of imatinib in relation to therapeutic outcome in chronic myeloid leukemia patients

The Tyrosine Kinase Inhibitors Imatinib and Dasatinib Reduce Myeloid Suppressor Cells and Release Effector Lymphocyte Responses

Christiansson, Lisa; Söderlund, Stina; Mangsbo, Sara; Hjorth-Hansen, Henrik et al.

Ingår i Molecular Cancer Therapeutics, s. 1181-1191, 2015

• DOI för The Tyrosine Kinase Inhibitors Imatinib and Dasatinib Reduce Myeloid Suppressor Cells and Release Effector Lymphocyte Responses

Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006)

Hjorth-Hansen, Henrik; Stenke, Leif; Söderlund, Stina; Dreimane, Arta et al.

Ingår i European Journal of Haematology, s. 243-250, 2015

• DOI för Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006)
• Ladda ner fulltext (pdf) av Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006)

PROGRESSION OF CHRONIC PHASE CHRONIC MYELOID LEUKEMIA TO ADVANCED PHASE ON TKI THERAPY: A POPULATION BASED ANALYSIS FROM THE SWEDISH CML REGISTER

Söderlund, Stina; Dahlen, T.; Creignou, M.; Sandin, F. et al.

Ingår i Haematologica, s. 233-233, 2015

Mature, Adaptive-like CD56(DIM) NK Cells in Chronic Myeloid Leukemia Patients in Treatment Free Remission

Ilander, Mette; Schlums, Heinrich; Olsson-Strömberg, Ulla; Lahteenmaki, Hanna et al.

Ingår i Blood, 2015

Disease Relapse After Tyrosine Kinase Inhibitor Treatment Discontinuation in Chronic Myeloid Leukaemia is Related to Both Low Number and Impaired Function of NK Cells

Ilander, Mette; Olsson-Strömberg, Ulla; Lahteenmaki, Hanna; Kasanen, Tiina et al.

Ingår i Scandinavian Journal of Immunology, s. 467-468, 2014

Musculoskeletal pain in patients with chronic myeloid leukemia after discontinuation of imatinib: a tyrosine kinase inhibitor withdrawal syndrome?

Richter, Johan; Söderlund, Stina; Lübking, Anna; Dreimane, Arta et al.

Ingår i Journal of Clinical Oncology, s. 2821-2823, 2014

• DOI för Musculoskeletal pain in patients with chronic myeloid leukemia after discontinuation of imatinib: a tyrosine kinase inhibitor withdrawal syndrome?

Early Disease Relapse after Tyrosine Kinase Inhibitor Treatment Discontinuation in CML Is Related Both to Low Number and Impaired Function of NK-Cells

Ilander, Mette Matilda; Olsson-Strömberg, Ulla; Lahteenmaki, Hanna; Tiina, Kasanen et al.

Ingår i Blood, 2014

Increased Level of Myeloid-Derived Suppressor Cells, Programmed Death Receptor Ligand 1/Programmed Death Receptor 1, and Soluble CD25 in Sokal High Risk Chronic Myeloid Leukemia

Christiansson, Lisa; Söderlund, Stina; Svensson, Emma; Mustjoki, Satu et al.

Ingår i PLOS ONE, 2013

• DOI för Increased Level of Myeloid-Derived Suppressor Cells, Programmed Death Receptor Ligand 1/Programmed Death Receptor 1, and Soluble CD25 in Sokal High Risk Chronic Myeloid Leukemia
• Ladda ner fulltext (pdf) av Increased Level of Myeloid-Derived Suppressor Cells, Programmed Death Receptor Ligand 1/Programmed Death Receptor 1, and Soluble CD25 in Sokal High Risk Chronic Myeloid Leukemia

Clinical and Immunological Studies in Chronic Myeloid Leukaemia

Söderlund, Stina

2017

• Ladda ner fulltext (pdf) av Clinical and Immunological Studies in Chronic Myeloid Leukaemia